Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials

Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials

Abstract Background Many clinical trials have assessed the effect and safety of monoclonal antibodies (MAbs) in combination with proteasome inhibitors or immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma (MM). The treatment outcomes of comparing different MAbs in c...

Full description

Bibliographic Details
Main Authors: Wu Ye, Xia Wu, Xiaoyan Liu, Xue Zheng, Jili Deng, Yuping Gong
Format: Article
Language:English
Published: BMC 2021-09-01
Series:BMC Cancer
Subjects:
Monoclonal antibodies
CD38
SLAMF7
PD-1/PD-L1
Meta-analysis
Online Access:https://doi.org/10.1186/s12885-021-08588-9

Internet

https://doi.org/10.1186/s12885-021-08588-9

Similar Items